Hematologic Malignancy
Epipodophyllotoxin-Related Myelodysplastic Syndrome
CI-CAN-00005181Explore in graph →
Hematologic
- NCIt
- C7642
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005181Explore in graph →
Data completeness0 / 7 dimensions
Computed from entity_counters.completeness · refreshed after each connector run
Definition
A disorder seen following cancer chemotherapy. It typically manifests a few years after initiation of epipodophyllotoxin chemotherapy. Mutagenic potential of these non-intercalating DNA topoisomerase II inhibitors is believed to be increased with concurrent use of asparaginase or granulocyte colony-stimulating factor. Balanced translocations involving chromosomal bands 11q23 and 21q22 are commonly associated with this disorder. Clinical signs may include fatigue, dyspnea, bruising and frequent infections. Clinical course usually progresses to acute myeloid leukemia though most epipodophyllotoxin-related leukemias do not have an antecedent myelodysplastic phase. Prognosis is dismal with survivability usually less than one year.
Data updated 22 days agoSource updated 26.08e
Taxonomy
Several hierarchies coexist; edges are listed per hierarchy type with their source.
Parents
Children (0)
Leaf node — no children.
Anatomy
Data updated 10 hours agoSource updated unknowncounters aggregate over descendants
Names
CancerIndex is a research and information platform. It does not diagnose and does not recommend treatment.
Key figures
Each figure carries its unit, period and source; ranks link to "Why this rank?".
Data updated 10 hours agoSource updated unknownregistry figures: cdc-uscs · latest year available per metric · counters aggregate over descendants